Amicus Therapeutics to Announce Full-Year 2012 Financial Results on March 12, 2013

Amicus Therapeutics to Announce Full-Year 2012 Financial Results on March 12,
2013

CRANBURY, N.J., March 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced a conference call and live audio webcast on
Tuesday, March 12, 2013 at 5:00 p.m. ET to discuss financial results for the
full-year ended December 31, 2012.

The call with be hosted by John F. Crowley, Chairman and Chief Executive
Officer. He will be joined on the call by additional members of the Amicus
management team. Interested participants and investors may access the
conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or
678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the
Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days.
Web participants are encouraged to go to the web site 15 minutes prior to the
start of the call to register, download and install any necessary software.
The slide presentation for the conference call/webcast will also be available
at http://ir.amicustherapeutics.com/events.cfm.

A telephonic replay of the call will be available for seven days beginning at
8:00 p.m. ET on March 12, 2013. Access numbers for this replay are
855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code
20428058.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
small molecule drugs called pharmacological chaperones, a novel,
first-in-class approach to treating a broad range of human genetic diseases.
Amicus' late-stage programs for lysosomal storage disorders include migalastat
HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered
with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220
co-administered with ERT in Phase 2 for Pompe disease.

FOLD-G

CONTACT: Amicus Therapeutics
         Sara Pellegrino
         (609) 662-5044
         spellegrino@amicusrx.com